Find a Clinical Trial

Showing 41 - 50 of 180 Trials

  • A Phase II trial of avutometinib in combination with defactinib in metastatic diffuse gastric cancer

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06487221

    Population:

    Adult

    Phase:

    II
    There are two main types of stomach cancer based on the appearance under the microscope: intestinal-type and diffuse-type. Some stomach cancers also have a mix of intestinal-type and diffuse-type (mixed type). You are being invited to take part in this research study because you have been diagnosed with stomach cancer that has spread to other parts of the body and/or cannot be surgically removed, has diffuse-type or mixed-type cells or has gene alterations that are associated with diffuse-type stomach cancers (such as mutations in the genes CDH1 or RHOA), and you have already been treated...

  • Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05928806

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to find out if the combination of botensilimab and balstilimab is more effective and safer at treating in clear cell Renal Cell Cancer (ccRCC) [kidney cancer] that has spread to other parts of the body (metastatic) than the standard combination of nivolumab and ipilimumab. The combination of nivolumab and ipilimumab has already been approved by the Food and Drug Administration (FDA) for use in advanced kidney cancer. The combination of balstilimab and botensilimab is investigational and has not been approved by the Food and Drug Administration (FDA). Are you...

  • A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion

    Principal Investigator:

    Aya Haggiagi, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05859334

    Population:

    Adult

    Phase:

    II
    This study is being done to answer the following question: Will erdafitinib treatment be able to shrink or slow the growth of brain cancer that has returned or gotten worse after treatment? This study is being done to find out if treatment with erdafitinib is better or worse than the usual approach for your brain cancer. The usual approach is defined as care most people get for brain cancer: treatment with surgery, radiation, or FDA-approved drugs such as lomustine or bevacizumab. Sometimes, combinations of these treatments are used. Are you Eligible? (Inclusion Criteria) Are you 18 years of...

  • A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06534983

    Population:

    Adult

    Phase:

    II
    This study is testing a drug called autogene cevumeran in combination with nivolumab, a cancer treatment drug known for treating bladder cancer. The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus nivolumab versus nivolumab on patients with Muscle Invasive Urothelial Carcinoma (MIUC.) In this study, you will get either autogene cevumeran plus nivolumab or saline plus nivolumab. Autogene Cevumeran is not approved by the Food and Drug Administration to treat muscle-invasive urothelial cancer. Are you Eligible? (Inclusion Criteria) 18 years or older - For...

  • A phase 2 study of fixed therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

    Principal Investigator:

    Andrew H Lipsky, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06333262

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to learn about possible initial treatments for chronic lymphocytic leukemia (CLL). This study will evaluate the investigational drug pirtobrutinib in combination with the commercially available drug obinutuzumab to treat CLL. The U.S. Food and Drug Administration (FDA) has approved pirtobrutinib for the treatment of CLL that has returned (relapsed) or is resistant to other treatments. Pirtobrutinib i is not FDA approved for the first-time treatment of CLL. The FDA has approved obinutuzumab for the Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age...

  • A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FORINTENSIVE CHEMOTHERAPY

    Principal Investigator:

    Sunil Girish Iyer, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06456463

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received study treatment for their acute myeloid leukemia (AML) before. The combination of Tag with Ven and Aza is experimental and this combination of all 3 drugs is not approved by the United States Food and Drug Administration (FDA) for the treatment for patients with AML. Are you Eligible? (Inclusion Criteria) Are you 18 years or older? -Are you able to give written informed consent and be able to comply with all study...

  • An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

    Principal Investigator:

    Fabio M. Iwamoto, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04947319

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. “Investigational new drug” means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Bruton’s tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts...

  • A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03866382

    Population:

    Adult

    Phase:

    II
    This purpose of this study is to test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare genitourinary cancers that have no standard treatment options. Are you Eligible? (Inclusion Criteria) Do you have confirmed diagnosis of one of the following cancers? -small cell carcinoma of the bladder; -adenocarcinoma of the bladder; -squamous cell carcinoma of the bladder; -plasmacytoid urothelial carcinoma; -any penile cancer; -sarcomatoid renal cell carcinoma; -sarcomatoid urothelial carcinoma; -renal medullary carcinoma or other miscellaneous histologic variants of the...

  • AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04322318

    Population:

    Pediatrics/Adult

    Phase:

    II
    This is a Phase 2 study of patients for the treatment of patients with high risk Wilms tumors (including those with diffuse anaplastic Wilms tumor- DAWT) and those who have relapsed favorable histology Wilms tumor (FHWT). The main goal of the study is to find out whether treatment with chemotherapy consisting of vincristine/irinotecan; cyclophosphamide/carboplatin/etoposide; and vincristine/doxorubicin/cyclophosphamide) improves the survival of patients with newly diagnosed Stage 4 diffuse anaplastic Wilms tumor (DAWT) or Standard-Risk relapsed favorable histology Wilms tumor (SRrFHWT) as...

  • AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04546399

    Population:

    Pediatrics/Adult

    Phase:

    II
    This is a study looking at how well the combination treatment of Blinatumomab and Nivolumab works in patients with first relapse of B-cell Acute Lymphoblastic Leukemia (B-ALL) as compared to treatment with only Blinatumomab. In addition, it is looking at what effects, good and/or bad the treatment has. First relapse means that B-ALL has come back after the initial treatment a patient received for B-ALL. All patients will receive treatment with Blinatumomab, an antibody (protein) that targets a marker on B-ALL cells and then uses your immune system to kill the B-ALL cell. Some patients will...

Pages